In a Phase 3 study, a booster dose of the Pfizer/BioNTech coronavirus vaccine was shown to have excellent effectiveness against the Covid-19 coronavirus, with 95.6 percent protection, according to the companies' announcement.
It was observed that efficacy was constant across all age groups and genders, as well as across races, ethnicities, and concomitant illnesses.
Pfizer and BioNTech stated that throughout the trial, there were 109 instances of Covid-19 among individuals who got a placebo and five cases among people who received the third dose of the vaccine, according to their findings.
The firms said that the vaccination effectiveness they discovered, 95.6 percent, represents a decrease in illness among individuals who got a booster injection compared to those who did not get a booster shot.
According to the businesses, these are the first findings from a randomized, controlled Covid-19 vaccine booster study, and they were obtained at a time when the highly infectious Delta version was in widespread use.
More than 10,000 fully vaccinated adults, ages 16 and above, participated in the study.
They were assigned to receive either the 30-microgram booster dose of vaccine or a placebo, which was administered randomly.
"These results provide further evidence of the benefits of boosters as we aim to keep people well-protected against this disease," Albert Bourla, Pfizer's chairman and chief executive officer, said in a news release Thursday.
The Advisory Committee on Immunization Practices of the United States Centers for Disease Control and Prevention will meet on Thursday to determine whether to recommend the FDA's recent mix-and-match permission, as well as the authorization of Moderna and J&J boosters, be recommended.
Comments / 6